I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project
Global CDMO utilizes Seattle facility’s mammalian biologics expertise to support late-stage clinical trials for leading international biopharma organization Seattle, Dec. 13, 2021 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment